FDA Hatch/Waxman Fix Proposal Includes “Beefed-Up” Patent Declarations
This article was originally published in The Tan Sheet
Executive Summary
FDA is considering requiring innovator companies to provide more information about patents they file for listing in the Orange Book as one way of addressing Hatch/Waxman loopholes
You may also be interested in...
FTC Backs Single 30-Month Stay On Generic Approvals In Patent Litigation
The Federal Trade Commission supports a limit of one 30-month stay of approval on generic drugs in patent litigation
Senate Generic Drug Bill Would Allow Challenges To Orange Book Listings
The amended version of the McCain/Schumer generic drug legislation would allow generic companies to sue patent holders for not providing correct and complete information about Orange Book listings
FDA Review Standards “Inconsistent” For New Drugs, Generics, PhRMA Says
The lack of an integrated review staff for new drugs and generics has led to "inconsistent" review standards between new drug divisions and the Office of Generic Drugs, the Pharmaceutical Research & Manufacturers of America says in a "white paper" submitted to FDA